Rozlytrek vs. Tagrisso

Rozlytrek (entrectinib) and Tagrisso (osimertinib) are kinase inhibitors indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC).

Rozlytrek is also used to treat adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.

Side effects of Rozlytrek and Tagrisso that are similar include fatigue, constipation, diarrhea, nausea, and cough.

Side effects of Rozlytrek that are different from Tagrisso include changes in taste, fluid retention/swelling (edema), dizziness, impaired sense of touch, shortness of breath, muscle pain, cognitive impairment, weight gain, vomiting, fever, joint pain, and vision disorders (blurred vision, light sensitivity, double vision, visual impairment, flashes of light, cataracts, and floaters).

Side effects of Tagrisso that are different from Rozlytrek include rash, dry skin, nail toxicity, decreased appetite, inflammation of the mouth and lips, itching, eye disorders, back pain, headache, pneumonia, and blood clots.

Both Rozlytrek and Tagrisso may interact with strong or moderate CYP3A inhibitors or inducers and medications that prolong the QT/QTc interval.

Rozlytrek may also interact with grapefruit and grapefruit products and strong or moderate CYP3A inhibitors.

Tagrisso may also interact with macrolide antibiotics, antifungals, antivirals, nefazodone, phenytoin, rifampicin, St. John's Wort, fentanyl, cyclosporine, quinidine, ergot alkaloids, and carbamazepine.

Common side effects of Rozlytrek include:

• fatigue,
• constipation,
• changes in taste,
• fluid retention/swelling (edema),
• dizziness,
• diarrhea,
• nausea,
• impaired sense of touch,
• shortness of breath,
• muscle pain,
• cognitive impairment,
• weight gain,
• cough,
• vomiting,
• fever,
• joint pain, and
• vision disorders
• blurred vision,
• light sensitivity,
• double vision,
• visual impairment,
• flashes of light,
• cataracts, and
• floaters

Side effects of Tagrisso nclude<:/p>

• diarrhea,
• rash,
• dry skin,
• nail toxicity,
• nausea,
• decreased appetite,
• constipation,
• inflammation of the mouth and lips,
• itching,
• eye disorders,
• cough,
• fatigue,
• back pain,
• headache,
• pneumonia, and
• blood clots.

Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive; and adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.

Tagrisso (osimertinib) is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy.

Rozlytrek may interact with grapefruit and grapefruit products, strong or moderate CYP3A inhibitors or inducers, and medications that prolong the QT/QTc interval. Tell your doctor all medications and supplements you use. Rozlytrek is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Rozlytrek and for 5 weeks following the final dose. Males with female partners of reproductive potential are advised to use effective contraception during treatment with Rozlytrek and for 3 months after the final dose. It is unknown if Rozlytrek passes into breast milk. Because of the potential adverse reactions in breastfed children, breastfeeding is not recommended during treatment with Rozlytrek and for 7 days after the final dose.

Tagrisso may interact with macrolide antibiotics, antifungals, antivirals, nefazodone, phenytoin, rifampicin, St. John's Wort, fentanyl, cyclosporine, quinidine, ergot alkaloids, and carbamazepine. Tell your doctor all medications and supplements you use. Tagrisso is not recommended for use during pregnancy; it may harm a fetus. Breastfeeding is not recommended during treatment with Tagrisso.

The recommended dosage of Rozlytrek for ROS1-Positive non-small cell lung cancer is 600 mg orally once daily. The recommended adult dosage of Rozlytrek for NTRK gene fusion-positive solid tumors is 600 mg orally once daily. The recommended dosage of Rozlytrek is based on body surface area.

The dose of Tagrisso is 80 mg orally once daily, with or without food.